Cat. #153261
Anti-BCRABL [7c6] rAb
Cat. #: 153261
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: BCRABL
Class: Recombinant
Application: IF ; IP ; WB
Reactivity: Human
Host: Mouse
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Susheela Dhut
Institute: Absolute Antibody ; Queen Mary University of London
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-BCRABL [7c6] rAb
- Clone: 7c6
- Tool sub type: Primary antibody
- Class: Recombinant
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: IF ; IP ; WB
- Description: Recombinant antibody directed against BCR-ABL oncoprotein. Background and Research Application The BCR gene is involved in the 9:22 translocation that generates the Philadelphia chromosome both in chronic myeloid leukaemia (CML) and in a proportion of cases of acute lymphocytic leukaemia (ALL). A 5' bcr sequence becomes fused to an abl sequence (including tyrosine kinase domain sequences) from chromosome 9. This results in the production of a chimeric BCR-ABL oncoprotein with constitutively active tyrosine kinase activity. This is a recombinant version of anti-BCRABL monoclonal antibody. Anti-BCRABL antibody may be useful for studies of the oncogene and have potential diagnostic and prognostic applications, particularly within leukaemia. This antibody is specific for the SSINEEITPRRQS epitope of BCR (residues 686-696), and as such is able to recognise full-length BCR and the p210 form of the BCR-ABL fusion protein.
- Immunogen: Bcr686 thyroglobulin conjugate
- Immunogen uniprot id: Q62199
- Isotype: IgG2a
Target Details
- Target: BCRABL
- Target background: Recombinant antibody directed against BCR-ABL oncoprotein. Background and Research Application The BCR gene is involved in the 9:22 translocation that generates the Philadelphia chromosome both in chronic myeloid leukaemia (CML) and in a proportion of cases of acute lymphocytic leukaemia (ALL). A 5' bcr sequence becomes fused to an abl sequence (including tyrosine kinase domain sequences) from chromosome 9. This results in the production of a chimeric BCR-ABL oncoprotein with constitutively active tyrosine kinase activity. This is a recombinant version of anti-BCRABL monoclonal antibody. Anti-BCRABL antibody may be useful for studies of the oncogene and have potential diagnostic and prognostic applications, particularly within leukaemia. This antibody is specific for the SSINEEITPRRQS epitope of BCR (residues 686-696), and as such is able to recognise full-length BCR and the p210 form of the BCR-ABL fusion protein.
Applications
- Application: IF ; IP ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS
- Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
- Shipping conditions: Shipping at 4° C
Related Tools
- Related tools: Anti-BCRABL [7c6]
References
- Original hybridoma first published in: Walker et al. 1987. Nature. 329(6142):851-3. PMID: 3478595.